CHANGES IN BLOOD COAGULATION PARAMETERS FOLLOWING CHRONIC MUMIYO ADMINISTRATION IN DOGS
DOI:
https://doi.org/10.55640/Keywords:
Mumiyo, blood coagulation, anticoagulant activity, fibrinolysis, coagulation factors, chronic experiment, Persian medicine, Arabic medicine, World Health Organization.Abstract
The present study evaluated the effects of chronic oral administration of mumiyo on the blood coagulation system in dogs. Five clinically healthy adult dogs of both sexes were administered mumiyo at a dose of 300 mg/kg body weight once daily. Blood samples were collected before treatment and on days 3, 5, and 6 of administration to assess coagulation parameters. Blood clotting time, plasma recalcification time, plasma tolerance to heparin, heparin time, thrombin time, coagulation factors II and V, and fibrinolytic activity were analyzed. Data were expressed as mean ± SD, and statistical comparisons were performed using Student’s paired t-test. Mumiyo administration produced significant, time-dependent changes in hemostasis. Blood clotting time, plasma recalcification time, heparin time, plasma tolerance to heparin, and thrombin time were significantly prolonged compared with baseline values. Coagulation factors II and V showed significant increases at later stages of the experiment, while fibrinolytic activity was significantly altered throughout the study period. Despite partial compensatory changes in coagulation factors, the overall effect of mumiyo was characterized by a pronounced hypocoagulant and anticoagulant action.
Downloads
References
1. World Health Organization (WHO), 2000. General guidelines for methodologies on research and evaluation of traditional medicine. World Health Organization, Geneva.
2. Shahriari M, Zare F, Nimrouzi M. The Curative Role of Bitumen in Traditional
Persian Medicine. Acta Med Hist Adriat. 2018;16(2):283-92
3. Ghosal S. 2006. Shilajit in Perspective. Narosa Publishing House, New Delhi India.
4. Olivieri MF, Marzari F, Kesel AJ, Bonalume L, Saettini F. Pharmacology and psychiatry at the origins of Greek medicine: The myth of Melampus and the madness of the Proetides. J Hist Neurosci. 2017;26(2):193-215.
5. Wilson E, Rajamanickam GV, Dubey GP,et al.2011. Review on shilajit used in traditional Indian medicine.J Ethnopharmacol 136:1–9
6. Schepetkin I, Khebnikov A, Kwon BS. 2002. Medical drugs from humus matter: focus on mumie.Drug Devel Res57: 140–159
7. Shirbeigi L ZA, Naghizadeh A, Alizadeh Vaghasloo M. The Concept of Temperaments in Traditional Persian Medicine. Trad Integr Med. 2017;2(3):143-56.
8. Frolova N, Kiseleva L, Tatiana. Chemical composition of mumijo and methods for determining its authenticity and quality (a review). Pharma Chem J. 1996;30(8):543-7.
9. Agarwal SP, Khanna R, Karmarkar R, Anwer MK, Khar RK. Shilajit: a review. Phytother Res. 2007;21(5):401-5.
10. Verma A, Kumar N, Gupta L, Chaudhary S. Shilajitin Cancer Treatment: Probable Mode of Action. Int J Pharmaceutic Bio Arch. 2016;7(1):12-6.
11. Stohs SJ, Singh K, Das A, Roy S, Sen CK. 12-Energy and Health Benefits of Shilajit. In: Bagchi D, editor. Sustained Energy for Enhanced Human Functions and Activity. Academic Press; 2017. p. 187-204
12. Ghosal S, Lal J, Singh SK, Goel RK, Jaiswal AK, Bhattacharya SK. The need for formulation of Shilajit by its isolated active constituents. Phytother Res. 1991;5(5):211-6
13. Trivedi N, Mazumdar B, Bhatt J, Hemavathi K. Effect of shilajit on blood glucose and lipid profile in alloxaninduced diabetic rats. Indian J Pharmacol. 2004;36(6):373-6.
14. Загрутдинов, Ф. Ф., Мамадалиев, Ш. И., & Болтабоева, Д. Ф. (2024). Влияние Среднеазиатских Видов Мумиё на диурез и натрий урез у Крыс. Open Herald: Periodical of Methodical Research, 2(5), 12-14.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India